表紙
市場調査レポート

ANCA関連血管炎 - パイプライン製品の分析

Anca Vasculitis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 321935
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ANCA関連血管炎 - パイプライン製品の分析 Anca Vasculitis - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 59 Pages
概要

ANCA関連血管炎は自己抗体による自己免疫疾患で、疲労感、体重減少、熱、息切れ、関節痛、血痰、鼻血/血性鼻漏、鼻の潰瘍、難聴などが症状として現れます。

当レポートでは、ANCA関連血管炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ANCA関連血管炎の概要

ANCA関連血管炎 - 治療薬の開発

  • パイプライン製品:概要

開発中の治療薬:企業別

ANCA関連血管炎 - パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

ANCA関連血管炎 - 開発中の製品:企業別

ANCA関連血管炎 - 治療薬の開発に従事している企業

  • ChemoCentryx, Inc.
  • GlaxoSmithKline plc
  • Kineta, Inc.

ANCA関連血管炎 - 治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • belimumab
  • CCX-1378
  • CCX-168
  • dalazatide
  • mepolizumab

ANCA関連血管炎 - 最新のパイプライン情報

ANCA関連血管炎 - 開発休止中のプロジェクト

ANCA関連血管炎 - 製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7795IDB

Summary

Global Markets Direct's, 'Anca Vasculitis - Pipeline Review, H1 2016', provides an overview of the Anca Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anca Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anca Vasculitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anca Vasculitis
  • The report reviews pipeline therapeutics for Anca Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anca Vasculitis therapeutics and enlists all their major and minor projects
  • The report assesses Anca Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anca Vasculitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anca Vasculitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anca Vasculitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anca Vasculitis Overview
  • Therapeutics Development
    • Pipeline Products for Anca Vasculitis - Overview
  • Anca Vasculitis - Therapeutics under Development by Companies
  • Anca Vasculitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Anca Vasculitis - Products under Development by Companies
  • Anca Vasculitis - Companies Involved in Therapeutics Development
    • ChemoCentryx, Inc.
    • GlaxoSmithKline Plc
    • Kineta, Inc.
  • Anca Vasculitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • belimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCX-1378 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mepolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anca Vasculitis - Recent Pipeline Updates
  • Anca Vasculitis - Dormant Projects
  • Anca Vasculitis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168
      • Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting
      • Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
      • Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements
      • Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis
      • Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anca Vasculitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Anca Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2016
  • Anca Vasculitis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Anca Vasculitis - Pipeline by Kineta, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Anca Vasculitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Anca Vasculitis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Anca Vasculitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top